Constipation sibutramine

Sibutramine is more effective than placebo with the most significant weight loss during the first 6 months of use. Dry mouth, anorexia, insomnia, constipation, increased appetite, dizziness, and nausea occur two to three times more often than with placebo. Sibutramine should not be used in patients with coronary artery disease, stroke, congestive heart failure, arrhythmias, or monoamine oxidase inhibitor use. 

The newest appetite suppressant, sibutramine (Meridia), works by blocking the reuptake of both serotonin and norepinephrine. It does not stimulate nerve cells to release serotonin, as do fenfluramine and dexfenfluramine. Administered at 20 mg/ day, sibutramine effectively reduces weight in obese patients, but its use has not been assessed in eating disorder patients. The most common side effects of this medication are insomnia, dry mouth, and constipation. It has not been associated with the more serious heart and lung complications observed with fenfluramine and dexfenfluramine. Because sibutramine acts in part through modulation of norepinephrine, there is no rational basis for coadministering phentermine, which acts via this same mechanism. 

Besides common usually mild side effects such as dry mouth, constipation, insomnia, and headaches, sibutramine produces a dose-dependent minor increase in heart rate and may increase the blood... 

The most commonly occurring ADRs reported in >5% of patients using the agent was mania, panic attacks, psychosis, increased risk of myocardial infarct, rash, abdominal pain, constipation, increased/decreased appetite, indigestion, nausea, xerostomia, arthralgia, backache, headache, dizziness, nervousness, said flu-like illness [32 ] [63 ] [64 ]. Sibutramine was withdrawn from the US Market in 2010. 

---